Peter Soparkar - Mar 8, 2022 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
Chief Operating Officer and Chief Legal Officer
Signature
Peter Soparkar, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
ADVM
Transactions as of
Mar 8, 2022
Transactions value $
$0
Form type
4
Date filed
3/17/2022, 04:51 PM
Previous filing
Dec 10, 2021
Next filing
Apr 20, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADVM Stock Option (Right to Buy) Award $0 +255K $0.00 255K Mar 8, 2022 Common Stock 255K $1.29 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 18, 2022 (the "Vesting Commencement Date"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Remarks:

Chief Operating Officer and Chief Legal Officer